RespiriTB
Description
Progress new assets (one pre-new molecular entity and one first-time-in-human start) for tuberculosis that act synergistically with bedaquiline, cytochrome bc or cytochrome bd inhibitors
Accession number
f32fb9f2-5f11-11eb-917b-acde48001122
Project acronym
RespiriTB
Project website
Start date
2019-05-01
End date
2025-04-30
Funding
IMI2 - Call 16 (Grant number 853903)
Types
